

FORM PTO 1449 (modified)		DEC 22 2005	ATTY DOCKET NO. 01997.O043600	APPLICATION NO. 10/620,169			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		APPLICANT	GRUSBY et al.				
		FILING DATE July 15, 2003	GROUP 1647				
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
FH		Bazan "Structural design and molecular evolution of a cytokine receptor superfamily," Proc. Natl. Acad. Sci. USA 87:6934-38 (1990)					
FH		Imler et al. "Identification of three adjacent amino acids of interleukin-2 receptor β chain which control the affinity and the specificity of the interaction with interleukin-2," EMBO J. 11:2047-53 (1992)					
FH		LaRosa et al. "Amino Terminus of the Interleukin-8 Receptor Is a Major Determinant of Receptor Subtype Specificity," J. Biol. Chem. 267:25402-06 (1992)					
FH		Schimmenti et al. "Localization of an essential ligand binding determinant of the human erythropoietin receptor to a domin N-terminal to the WSXWS motif: implications for soluble receptor function," Exp. Hematol. 23:1341-46 (1995)					
FH		Mulhern et al. "The Solution Structure of the Cytokine-binding Domain of the Common β -Chain of the Receptors for Granulocyte-Macrophage Colony-stimulating Factor, Interleukin-3 and Interleukin-5," J. Mol. Biol. 297:989-1001 (2000)					
FH		Woodcock et al. "Three residues in the common β chain of the human GM-CSF, IL-3 and IL-5 receptors are essential for GM-CSF and IL-5 but not IL-3 high affinity binding and interact with Glu21 of GM-CSF," EMBO J. 13:5176-85 (1994)					
EXAMINER		<i>John H. H. H. H.</i>		DATE CONSIDERED	3/1/06		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.